In August, Johnathon Seth Parham, MD and Anne Carol Goldberg, MD, FACP had their review titled “Major Concepts in Treatment with Bempedoic Acid and Inclisiran that Clinicians Need To Know,” published in “Current Atherosclerosis Reports.”
The review looks at two new lipid-lowering treatment medications, bempedoic acid and inclisiran. “Bempedoic acid inhibits adenosine citrate lyase, decreasing intracellular lipogenesis” and “inclisiran uses RNA interference to prevent translation of PCSK9 mRNA. Due to its stability, it can be given as an injection every 6 months and produces consistent, durable, and potent cholesterol lowering.”
Their findings suggest that these concepts offer new avenues to prevention and treatment of cardiovascular disease.
Major Concepts in Treatment with Bempedoic Acid and Inclisiran that Clinicians Need To Know